The analysis included 3,623 stable post-MI patients with left ventricular ejection fraction (LVEF) ≥40% who were randomized to β-blocker interruption or continuation. Key findings from this pre-specified analysis study include:● β-Blocker Interruption Caused Dose-Dependent Heart Rate Rebound with Increased Cardiovascular Risk: β-blocker interruption led to significant and sustained heart rate increases with a dose-dependent rebound effect and higher cardiovascular event risk across all three heart rate tertiles, though more pronounced in patients with elevated baseline heart rate (≥68 bpm). Beta-blocker interruption resulted in sustained heart rate elevation across all tertiles, with the most pronounced rebound in patients with higher baseline heart rates. Figures 1 and 2 illustrate the distribution of clinical outcomes across heart rate tertiles (HR <60 bpm, HR 60–<68 bpm, and HR ≥68 bpm). All-Cause Mortality:p <0.001, Cardiovascular Death: p = 0.014, Recurrent MI: p = 0.040Figure 2: Composite Endpoints: MACE, MACE + HF Hospitalization, Primary Composite.